We are submitting a proposal for a MSCIDA in Pediatric Pharmacology to support the training and career development of Yewande J. Johnson, M.D. Dr. Johnson is a junior pediatric anesthesiologist who wants to dedicate her training and career to the field of Pediatric Clinical Pharmacology. She has already participated in several clinical trials with analgesic drugs in children and wants to develop skills in designing, executing, and interpreting pediatric drug trials. In addition, Dr. Johnson wants to understand regulatory issues dealing with pediatric labeling of drugs. Significant institutional and departmental commitments, including financial support have been provided to build a premier academic pediatric clinical pharmacology research program at Children's National Medical Center (CNMC) and Dr. Johnson will fully be embedded in this existing program. Dr. van den Anker, the P.I. of this proposal and primary mentor of Dr. Johnson, has received substantial NIH-funding (U10, K24 and R01) to guarantee resources and dedicated time to Dr. Johnson during her clinical pharmacology training period. In addition, Dr. van den Anker is one of the core faculty members of the NIGMS-funded Clinical Pharmacology Training Grant (T32) at Georgetown University (GU) that will guarantee Dr. Johnson with participation in this fully accredited Training Program in Clinical Pharmacology and will allow her to sit for the Certification Exam of the American Board of Clinical Pharmacology. Additionally she also will participate in the training program for clinical researchers available at CNMC/GU. Her research proposal to develop a non-invasive assessment of opiate analgesia in children with sickle cell disease will not only be an integral part of her training but also be a clinical research topic tailored to her needs. Her project involves pharmacokinetics, pharmacokinetic/pharmacodynamic (PK/PD) modeling, pharmacogenetics in addition to the development of a reliable child friendly non-invasive pharmacodynamic assessment tool. Dr. Johnson's research will result in an assessment tool that probably will be useful for pediatric patients of all ages with acute and chronic pain and therefore represent a very important and timely research topic. In addition to her general training in pharmacogenomics/pharmacogenetics/proteomics and PK/PD modeling she will have a 4-week rotation in pediatric pharmacogenetics and a 4-week rotation in pediatric aspects of PK-PD modeling to further optimize her training experience. ? ? ? ? ?
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2013) Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. Pediatr Res 74:721-9 |
| Best, Brookie M; Capparelli, Edmund V; Diep, Huy et al. (2011) Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr 58:385-91 |
| Rakhmanina, Natella Y; Neely, Michael N; Van Schaik, Ron H N et al. (2011) CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit 33:417-24 |
| Rakhmanina, Natella Y; van den Anker, John N (2010) Treating an HIV-infected paediatric patient: an easy task? Antivir Ther 15:293-6 |
| Leeder, J Steven; Kearns, Gregory L; Spielberg, Stephen P et al. (2010) Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 50:1377-87 |
| Rakhmanina, Natella Y; van den Anker, John N (2010) Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 6:95-103 |
| Rakhmanina, Natella Y; van den Anker, John N; Soldin, Steven J et al. (2010) Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit 32:273-81 |
| Khan, M; Song, X; Williams, K et al. (2009) Evaluating adherence to medication in children and adolescents with HIV. Arch Dis Child 94:970-3 |
| Allegaert, Karel; Vanhaesebrouck, Sophie; Verbesselt, Rene et al. (2009) In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 31:411-5 |
| Knibbe, Catherijne A J; Krekels, Elke H J; van den Anker, Johannes N et al. (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48:371-85 |
Showing the most recent 10 out of 40 publications
